259- Ramos-Casals M, et al. Autoimmune diseases induced by biological agents: a double-edged
sword? Autoimmun Rev. 2010;9(3):188–93. - Jacobson DL, et al. Epidemiology and estimated population burden of selected autoimmune
diseases in the United States. Clin Immunol Immunopathol. 1997;84(3):223–43. - van Oosten BW, et al. Increased MRI activity and immune activation in two multiple sclerosis
patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology.
1996;47(6):1531–4. - Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy.
Neurology. 2001;57(10):1885–8. - Mohan N, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for
inflammatory arthritides. Arthritis Rheum. 2001;44(12):2862–9. - Enayati PJ, Papadakis KA. Association of anti-tumor necrosis factor therapy with the devel-
opment of multiple sclerosis. J Clin Gastroenterol. 2005;39(4):303–6. - Bellesi M, et al. CNS demyelination during anti-tumor necrosis factor alpha therapy. J Neurol.
2006;253(5):668–9. - Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported
in association with tumor necrosis factor alpha antagonism: by what mechanisms could
tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple
sclerosis? Arthritis Rheum. 2001;44(9):1977–83. - Andreadou E, et al. Demyelinating disease following anti-TNFa treatment: a causal or coin-
cidental association? Report of four cases and review of the literature. Case Rep Neurol Med.
2013;2013:671935. - Gupta G, Gelfand JM, Lewis JD. Increased risk for demyelinating diseases in patients with
inflammatory bowel disease. Gastroenterology. 2005;129(3):819–26. - Kaltsonoudis E, et al. Neurological adverse events in patients receiving anti-TNF therapy: a
prospective imaging and electrophysiological study. Arthritis Res Ther. 2014;16(3):R125. - Khoury SJ, et al. Acquired tolerance to experimental autoimmune encephalomyelitis by
intrathymic injection of myelin basic protein or its major encephalitogenic peptide. J Exp
Med. 1993;178(2):559–66. - van Boxel-Dezaire AH, et al. Decreased interleukin-10 and increased interleukin-12p40
mRNA are associated with disease activity and characterize different disease stages in mul-
tiple sclerosis. Ann Neurol. 1999;45(6):695–703. - Noseworthy JH, et al. Multiple sclerosis. N Engl J Med. 2000;343(13):938–52.
- Kwon HJ, et al. Case reports of heart failure after therapy with a tumor necrosis factor antago-
nist. Ann Intern Med. 2003;138(10):807–11. - Levine B, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart
failure. N Engl J Med. 1990;323(4):236–41. - Bozkurt B, et al. Results of targeted anti-tumor necrosis factor therapy with etanercept
(ENBREL) in patients with advanced heart failure. Circulation. 2001;103(8):1044–7. - Deswal A, et al. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel,
etanercept) in patients with advanced heart failure. Circulation. 1999;99(25):3224–6. - Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of
the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol.
2002;86(2–3):123–30. - Coletta AP, et al. Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and
ATTACH. Eur J Heart Fail. 2002;4(4):559–61. - Chung ES, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a
chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-
to- severe heart failure: results of the anti-TNF therapy against congestive heart failure
(ATTACH) trial. Circulation. 2003;107(25):3133–40. - Schiff MH, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and
US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis.
2006;65(7):889–94.
14 Noninfectious and Nonmalignant Complications of Anti-TNF Therapy